Skip to main content
Figure 6 | Breast Cancer Research

Figure 6

From: CIP2A is a target of bortezomib in human triple negative breast cancer cells

Figure 6

Variable CIP2A expression in breast tumor tissue from patients with triple negative breast cancers. Representative results of immunohistochemical staining for CIP2A in breast tumor tissue from patients with triple negative breast cancers, showing variable degree of CIP2A expression ranging from negative (A), weak (B), moderate (C), and strong (D) expression. E. Detection of human CIP2A cytoplasmic expression in colon carcinoma (left) and ovarian carcinoma (middle) by immunohistochemistry was used as positive control. Primary CIP2A antibody omitted and replaced by phosphate-buffered saline was performed as negative control in TNBC (right). (High power, 400X).

Back to article page